Immunoglobulin - ProMetic Life Sciences

Drug Profile

Immunoglobulin - ProMetic Life Sciences

Alternative Names: IVIG - ProMetic Life Sciences

Latest Information Update: 04 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NantPharma; ProMetic Life Sciences
  • Class Immunoglobulin isotypes
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Immunodeficiency disorders

Most Recent Events

  • 30 Apr 2018 Safety and efficacy data from a phase III trial in Immunodeficiency disorders released by ProMetic Life Sciences
  • 22 Nov 2017 Prometic Life Sciences announces intention to submit New Drug Submission to Health Canada for Immunodeficiency disorders
  • 09 Aug 2016 ProMetic announces intention to submit BLA to US FDA in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top